Every material Form 8-K Beam Therapeutics Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Beam Therapeutics reported third quarter 2026 results on November 3, 2026, with a net loss of $134.4 million, or $1.28 per share, up from $112.6 million, or $1.10 per share, a year earlier. License and collaboration revenue fell to $307,000 from $9.7 million, and cash, cash equivalents and marketable securities declined to $1.0 billion. The company said its cash plus an expected $200 million from its Sixth Street facility should fund operations into mid-2029, and that a U.S. BLA submission for risto-cel is expected as early as year-end 2026.
License and collaboration revenue was $307,000 in Q3 2026 versus $9.7 million in Q3 2025.
Net loss was $134.4 million, or $1.28 per share, versus $112.6 million, or $1.10 per share, a year earlier.
R&D expenses were $110.1 million and G&A expenses were $31.5 million, up from $26.7 million.
Cash position was $1.0 billion as of September 30, 2026, versus $1.2 billion at December 31, 2025; runway extends into mid-2029.
Beam Therapeutics reported second quarter 2026 results on August 4, 2026. Net loss widened to $122.7 million, or $1.18 per share, from $102.1 million, or $1.00 per share, a year earlier, while license and collaboration revenue fell to $490,000 from $8.5 million. The company said it ended the quarter with $1.2 billion in cash and marketable securities and expects that cash, plus an additional $200 million from its Sixth Street facility, to fund operations into mid-2029.
Net loss of $122.7 million, or $1.18 per share, for Q2 2026, versus $102.1 million, or $1.00 per share, for Q2 2025
License and collaboration revenue of $490,000 for Q2 2026, versus $8.5 million for Q2 2025
R&D expenses of $95.1 million and G&A expenses of $31.9 million in Q2 2026
Cash, cash equivalents and marketable securities of $1.2 billion at June 30, 2026; runway expected into mid-2029
Beam Therapeutics reported first quarter 2026 results, with a net loss of $94.3 million, or $0.91 per share, compared with $108.3 million, or $1.23 per share, a year earlier. License and collaboration revenue rose to $31.7 million from $7.5 million, and the company ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities, which it says will fund operations into mid-2029.
Net loss was $94.3 million, or $0.91 per share, for the quarter ended March 31, 2026, versus $108.3 million, or $1.23 per share, a year earlier.
License and collaboration revenue was $31.7 million, up from $7.5 million in the first quarter of 2025.
R&D expenses were $104.5 million and G&A expenses were $34.4 million, compared with $98.8 million and $27.9 million a year earlier.
Cash runway is expected to support operations into mid-2029, including $100 million from the Sixth Street financing agreement and an anticipated additional $100 million from the Sixth Street facility.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Beam Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →